It’s 100% happens and we were not limited in what we
It’s 100% happens and we were not limited in what we could buy. Or when we could buy. Certain people at the company were and they were several times because I was involved with pricing and contracting that we were under a hold and we’re not allowed to buy or sell shares of our own company And I suppose we would be encouraged not to do the same with competitive companies, but if I wanted to buy something like Visa or Apple that wasn’t involved in biotech, then I was free to do so. Those holes were usually 1/4 at a time and those announcements came out of nowhere. Let’s say I wanted to sell stock next week because I’m buying a house and all of a sudden one afternoon you’re on a conference call and they tell you you’re under a hold for the next three months and you cannot buy or sell the company stock. It was quite scary for some because you were literally handcuffed.
But back to your question, yes if there was something that was learned at a conference about another company you certainly could purchase or sell stock because what you’re learning at the conference is public information. We only traded based on public information. I only bought stock in the companies. I worked for through employee stock, purchase plans, and stock option awards. I never purchased on the open market through brokerage account accounts. Those were used for other biotech companies.
Great question and great point. There will be a lot of talk at ESMO amongst people in the industry and people in the scientific community and medical community and they will be telling their colleagues. It’s kindling right now. The brushfire will start.
13
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Untapped Opportunities Between Africa and the Caribbean Who's ready to shake up the trade game between Africa and the Caribbean? According to a fresh-off-the-press report from the International Trade Centre (ITC) and Afreximbank, we could be looking at a whopping $1.65 billion in annual trade between these two regions by 2030. That's right, a billion with a 'B'. But let...
Continue Reading
New Chapter for Maysville: Speakeasy Opens Doors Normally, you'd think of medical cannabis expansions as dry numbers and policies, but with Speakeasy Dispensary making its mark in Maysville, it's not just about business; it's a service to the community. Nestled into 317 W 2nd St, this is more than a simple retail spot. It's about bringing medical options straight to the...
Continue Reading
Smarter Surveillance with Camect and 3Si A fresh collaboration is stirring the security pot, straight from Silicon Valley's buzzing tech nest. Camect, the brainiacs behind AI-powered video smarts, are shaking hands with 3Si Security Systems. In plain talk, they're hooking up Camect's sharp-eyed video tech with 3Si's DirectToDispatch™ system. This ain’t some techie...
Continue Reading
Meteor's Move: AET Labs Picked Up in CTE Plays You see, Meteor Education ain't sitting on its hands, that's for sure. They're out here hoarding strategic pieces like it's a chess match, snatching up AET Labs to bolster their already sturdy CTE playbook. No financial details spilled, but hell, that’s par for the course. This move plants them even more firmly in New...
Continue Reading
Setting the Stage at SEMA 2026 In the chaotic whirl of the 2026 SEMA Show, Massimo Group didn't just roll out new wheels—they took a leap into the big leagues. Amidst the bustling Vegas crowd, Massimo unveiled their latest babies: the Warrior 1500XD and the Sentinel 1500 HVAC Crew. These ain't just any UTVs; they're packing some serious muscle with a 1,499cc engine,...
Continue Reading
Lupin's Market Move: A Big Step in HIV Treatment There's a fresh gust blowing in the pharmaceutical skies today, as Lupin leaps ahead with the launch of their Raltegravir Tablets in the U.S. The company just bagged FDA approval, putting them on the front lines with a high-stake 180-day exclusivity period for their generic version. For investors keeping tabs on pharma...
Continue Reading
Big Moves in Textile Regeneration Now here's a move that's got the fabric world buzzing: Reju, the scrappy textile-to-textile regenerative powerhouse, is teaming up with six mills spread across Europe and the U.S. They’re setting the stage to crank up their polyester recycling game and flood the market with sustainable, eco-friendly fabrics. It's a bold step toward...
Continue Reading
Financial Milestones and Market Insights Boy, if you're not watching TETRA Technologies (NYSE:TTI) right now, you're probably missing out on a real barnstormer of a financial report. The numbers are looking chalkboards-be-damned stellar! They’ve just notched their finest third quarter in a decade, bringing in revenues through the roof at $168 million—an impressive 10%...
Continue Reading
An Invincible Maritime Shield When it comes to maritime intelligence, Windward just pulled a fast one. In a market where staying ahead of the game is like playing three-dimensional chess, they've snatched up Azimut.ai. This ain't some small fry; it's a visual intelligence firm poised to shore up Windward's grip on the elusive maritime world. Charting New Waters with...
Continue Reading
The Stakes of Carpet Care in Hawaii's Resorts Ah, Hawaii—the land of breathtaking beaches, vibrant luaus, and plush hotel carpets that take a beating every peak travel season. But before you brush off carpet care as mundane as a hollow coconut, let’s talk serious business. Renue Hawaii isn't fooling around with some one-size-fits-all cleaning routine. They’ve just...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding the Expanding Krill Meal Market The krill meal market is undergoing remarkable growth, fueled by a shift in consumer preferences favoring clean-label food products and natural flavor enhancers. According to recent estimates, the market is poised to expand significantly, reaching an impressive valuation by the end of an upcoming decade. This growth can be...
Continue Reading
Tango Therapeutics Begins Dosing in Pivotal Cancer Trial BOSTON — Tango Therapeutics, Inc. (NASDAQ: TNGX), a dynamic biotechnology company dedicated to revolutionizing cancer care, has achieved a pivotal milestone by dosing the first patient in its TNG456 Phase 1/2 trial aimed at patients with MTAP-deleted solid tumors, particularly glioblastoma (GBM). Known for its...
Continue Reading
Investors Encouraged to Join Class Action Against Rentokil Initial Bronstein, Gewirtz & Grossman, LLC, a well-respected law firm known for its expertise in securities cases, is reaching out to investors of Rentokil Initial Plc. This communication centers around a class action lawsuit that has been filed on behalf of those affected by some significant events concerning the...
Continue Reading
Murphy USA's Dividend Boost Reflects Confidence in Growth Murphy USA Inc. (NYSE: MUSA), a well-known player in the gasoline and convenience store sector, has recently announced an increase in its quarterly cash dividend. The company's Board has declared a new dividend of $0.48 per share, which represents a notable 6.7% rise from the previous dividend. This increase...
Continue Reading
Cloudinary's Innovative Update to Digital Asset Management Today, Cloudinary, the leading image and video platform, revealed significant advancements in its API-first digital asset management (DAM) solution. These enhancements are designed to address the evolving needs of brands in managing their visual assets efficiently and effectively. With a focus on streamlining...
Continue Reading